|

Mid-day market update: Crude oil rises 4%, Fennec Pharmaceuticals shares slide

Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 49,099,590 cases with around 799,410 deaths. India confirmed a total of at least 34,580,830 cases and 468,790 deaths, while Brazil reported over 22,080,900 COVID-19 cases with 614,310 deaths. In total, there were at least 261,877,540 cases of COVID-19 worldwide with more than 5,219,770 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Information technology shares gained by 1.8% on Monday. Meanwhile, top gainers in the sector included Matterport, Inc MTTR +16.87% (Get Free Alerts for MTTR), up 13% and Arqit Quantum Inc. ARQQ +6.21% (Get Free Alerts for ARQQ) up 10%.

In trading on Monday, financials shares fell 0.1%.

Top Headline

Li Auto Inc. LI +7.5% reported better-than-expected third-quarter financial results.

Li Auto reported third-quarter diluted earnings per ADS of 5 cents, which beat the estimate of a loss of 2 cents, and sales results of $1.21 billion, which beat the $1.16 billion estimate.

The company also reported deliveries of Li ONEs were 25,116 vehicles in the third quarter of 2021, representing a 190% year-over-year increase.

Equities Trading UP

Krystal Biotech, Inc. KRYS +116.58% shares shot up 123% to $88.75 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB).

Shares of Adagio Therapeutics, Inc. ADGI +69.03% got a boost, shooting 67% to $41.95 after the company said its COVID-19 monoclonal antibody, ADG20, is likely to retain activity against Omicron, as observed in in vitro models with all other variants of concern identified previously. Morgan Stanley upgraded Adagio Therapeutics from Equal-Weight to Overweight and announced a $49 price target.

NRx Pharmaceuticals, Inc. NRXP +22.44% shares were also up, gaining 29% to $8.72 after the company announced positive data from its ZYESAMI study.

Equities Trading DOWN

Fennec Pharmaceuticals Inc. FENC -48.86% shares tumbled 51% to $4.74 after the company said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark. The FDA indicated that, following a recent inspection of the manufacturing facility of the drug product manufacturer, deficiencies have been identified.

Shares of Allied Healthcare Products, Inc. AHPI -21.88% were down 20% to $6.64 after jumping around 55% on Friday.

Vaxxinity, Inc. VAXX -22.1% was down, falling 21% to $14.53. Vaxxinity, earlier during the month, priced its IPO at $13 per share.

Commodities

In commodity news, oil traded up 4% to $70.87, while gold traded up 0.1% to $1,786.20.

Silver traded down 0.8% Monday to $22.93 while copper rose 0.9% to $4.3285.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 gained 0.66%, the Spanish Ibex Index rose 0.62% and the German DAX 30 gained 0.01%. Meanwhile, the London’s FTSE 100 rose 1.02%, French CAC 40 gained 0.43% and Italy’s FTSE MIB climbed 0.63%.

Spain's annual inflation rate increased to 5.6% in November from 5.4% in the prior month. Producer prices in Italy jumped 20.4% year-over-year in October. Consumer credit in the UK rose by GBP 0.706 billion in October, while number of mortgage approvals for house purchase declined to 67.2 thousand in October.

Economics

The pending home sales index surged 7.5% for October, versus analysts’ expectations for a 0.9% growth.

The Dallas Fed manufacturing index dropped slightly to 11.8 in November from a three-month high level of 14.6 in October.

Federal Reserve Bank of New York President John Williams will speak at 3:00 p.m. ET.

Author

Benzinga Team

Benzinga's news desk is a dynamic and innovative team that provides real-time, actionable articles that help readers navigate the market.

More from Benzinga Team
Share:

Editor's Picks

EUR/USD shifts its attention to 1.1900 and above

EUR/USD has shaken off Tuesday’s dip, pushing back beyond the 1.1800 mark amid decent gains as  Wednesday’s session draws to a close. The rebound is largely driven by a modest pullback in the US Dollar, as markets digest the aftermath of President Trump’s SOTU speech and continue to monitor trade-related headlines and signals from the White House.
 

GBP/USD challenges multi-day highs near 1.3530

GBP/USD leaves behind the previous day’s decline and regains fresh upside traction on Wednesday, surpassing the 1.3500 barrier in a context of a modest decline in the Greenback and a generalised improved mood in the risk-linked space. Meanwhile, the US tariff narrative continues to dictate the mood among market participants after Presidet Trump’s SOTU speech failed to surprise markets.

Gold remains bid and close to $5,200

Gold buyers are returning to the fold on Wednesday, targeting the $5,200 area and possibly beyond, after Tuesday’s corrective dip from monthly highs. The rebound in the precious metal comes as the US Dollar loses traction, with Trump’s SOTU speech offering little fresh direction and AI-related nerves continuing to ease.

UK financial watchdog advances stablecoin oversight as four firms pilot issuance

The Financial Conduct Authority (FCA) in the United Kingdom (UK) is advancing toward the final stablecoin regulatory framework with a pilot program involving four companies, including Monee, Financial Technologies ReStabilise, Revolut and VVTX.

Nvidia earnings to influence AI trade and broader market sentiment

For the last three years, Nvidia has been the engine of the AI boom, and now Wall Street is watching to see whether that momentum can keep going. High-growth stocks have been struggling to maintain their bullish trend in 2026.

Cosmos Hub Price Forecast: ATOM rebounds slightly, bearish outlook remains intact

Cosmos Hub (ATOM) price rebounds, trading above $2.05 at the time of writing on Wednesday, after undergoing a sharp correction since last week. Weakening on-chain and derivatives data support a bearish outlook, while technical analysis remains unfavorable.